drugset / Trial / NCT02205606

Efficacy/Safety of HCP1306 Tablet Versus HGP0816 Tablet in Patients With Primary Hypercholesterolemia

NCT02205606

Phase 3 Completed 412 enrolled Hanmi Pharmaceutical Company Limited
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate efficacy and safety of HCP1306 in patients with primary hypercholesterolemia.

Timeline

Start
2014-06
Primary completion
2015-02
Completion
2015-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Ezetimibe Unknown 10 mg Oral
Subject Rosuvastatin Small molecule 5 mg Oral
Subject Rosuvastatin Small molecule 10 mg Oral
Subject Rosuvastatin Small molecule 20 mg Oral

Indications